IP Library Patent Application 15100302
Patent Application
App. No. 15/100,302

COMPOUND OF THE AVERMECTIN FAMILY OR OF THE MILBEMYCIN FAMILY FOR THE TREATMENT AND/OR PREVENTION OF ATOPIC DERMATITIS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
15/100,302
Abstract

A pharmaceutical composition is described that includes a compound of the avermectin family, possibly ivermectin, or a compound of the milbemycin family in a pharmaceutically acceptable carrier, for use in the treatment and/or prevention of atopic dermatitis.

Claims (48)

1 . A pharmaceutical composition comprising a compound of the avermectin family or of the milbemycin family in a pharmaceutically acceptable carrier, effective in the treatment of atopic dermatitis.

2 . The pharmaceutical composition as defined by claim 1 , wherein the compound of the avermectin family is selected from the group consisting of ivermectin, avermectin, abamectin, doramectin, eprinomectin and selamectin, aversectin B, AB or C, emamectin B1a, emamectin B1b and their derivatives.

3 . The pharmaceutical composition as defined by claim 2 , wherein the compound of the avermectin family is ivermectin.

4 . The pharmaceutical composition as defined by claim 1 , wherein the compound of the milbemycin family is selected from the group consisting of lepimectin, milbemectin, milbemycin oxime and moxidectin, 6′-ethyllepimectin, 6′-methyllepimectin and its derivatives or nemadectin α, β, γ or δ.

5 . The pharmaceutical composition as defined by claim 1 , wherein the composition is effective in the treatment of atopic dermatitis in pregnant women, children and/or infants.

6 . The pharmaceutical composition as defined by claim 5 , wherein the composition is effective in the treatment of atopic dermatitis in infants.

7 . The pharmaceutical composition as defined by claim 1 , wherein the composition is administered by topical application.

8 . The pharmaceutical composition as defined by claim 1 , wherein the composition is in the form of an emulsion, of a cream, of a lotion type, of a gel or of a solution.

9 . The pharmaceutical composition as defined by claim 1 , wherein the composition comprises from 0.001% to 5% by weight of a compound of the avermectin family or of the milbemycin family relative to the total weight of the composition.

10 . The pharmaceutical composition as defined by claim 9 , wherein the composition comprises in water:

Ivermectin

1.0

Glycerol

4.0

Acrylate C10-30 alkyl acrylate

0.2

Methyl para-hydroxybenzoate

0.2

Disodium EDTA

0.05

Citric acid monohydrate

0.05

Isopropyl palmitate

4.0

Cetyl alcohol

3.5

Stearyl alcohol

2.5

Oleyl alcohol

2.0

Ceteareth-20

3.0

Sorbitan monostearate

2.0

Dimethicone 200 20 cs

0.5

Propyl para-hydroxybenzoate

0.1

Propylene glycol

2.0

Phenoxyethanol

1.0

10% sodium hydroxide

qs pH

as % by weight relative to the total weight of the composition.

11 . The pharmaceutical composition as defined by claim 9 , wherein the composition comprises from 0.00% 1 to 0.3% by weight of a compound of the avermectin family or of the milbemycin family relative to the total weight of the composition.

12 . The pharmaceutical composition as defined by claim 10 , wherein the composition comprises from 0.001% to 0.05% by weight of a compound of the avermectin family or of the milbemycin family relative to the total weight of the composition.

13 . The pharmaceutical composition as defined by claim 1 , wherein the composition comprises from 0.001% to 1% by weight of a compound of the avermectin family or of the milbemycin family relative to the total weight of the composition.

Assignments (3)
ASSET TRANSFER AGREEMENT Recorded Oct 3, 2021
From: GALDERMA S.A.
To: NESTLÉ SKIN HEALTH S.A.
Reel/Frame 057698/0295 →
CHANGE OF NAME Recorded Oct 3, 2021
From: NESTLÉ SKIN HEALTH S.A.
To: GALDERMA HOLDING SA
Reel/Frame 057698/0356 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2016
From: HACINI-RACHINEL, FERIEL; VIAL, EMMANUEL; JOMARD, ANDRÉ
To: GALDERMA S.A.
Reel/Frame 038918/0240 →